Search results
Results from the WOW.Com Content Network
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes , from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis .
Lipoatrophy is most commonly seen in patients treated with thymidine analogues and other older HIV drug treatments such as the nucleoside reverse transcriptase inhibitors [NRTIs] [9] like zidovudine (AZT) and stavudine (d4T). [10] Other lipodystrophies manifest as lipid redistribution, with excess, or lack of, fat in various regions of the body ...
45 (10): 850–2. PMID 11077638. Meyer L, Hadjadj S, Guerci B, Delbachian I, Ziegler O, Drouin P (1998). "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion". Diabetes Metab. 24 (6): 544–6. PMID 9932222
In a sense, the "opposite" of injection site lipohypertrophy is injection site lipoatrophy, in which the subcutaneous fat around an injected area "melts away" over a few weeks or months, leaving unsightly, well-demarcated depressions in the skin. The mechanism of this local lipoatrophy is not understood and may involve autoimmunity or local ...
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4]
A 2010 phase 2 trial found cetilistat significantly reduced weight and was better tolerated than orlistat. [ 34 ] SGLT2 inhibitors cause the loss of 60–100 grams (2.1–3.5 oz) glucose in the urine each day and are associated with a modest, sustained weight loss of 1.5–2 kilograms (3.3–4.4 lb) in people with type 2 diabetes.
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome [1] and Lawrence–Seip syndrome, [1] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs.
Pioglitazone was patented in 1985, and came into medical use in 1999. [5] It is available as a generic medication. [3] In 2022, it was the 120th most commonly prescribed medication in the United States, with more than 5 million prescriptions. [6] [7] It was withdrawn in France and Germany in 2011. [8] [9] [10]